देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
AFATINIB (AFATINIB DIMALEATE)
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
L01EB03
AFATINIB
20MG
TABLET
AFATINIB (AFATINIB DIMALEATE) 20MG
ORAL
28
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0154930001; AHFS:
APPROVED
2013-11-01
_Pr_ _GIOTRIF® Product Monograph _ _ Page 1 of 44 _ PRODUCT MONOGRAPH PR GIOTRIF ® Afatinib Tablets 20, 30 and 40 mg afatinib (as afatinib dimaleate) Protein Kinase Inhibitor Boehringer Ingelheim (Canada) Ltd. 5180 South Service Road Burlington, Ontario L7L 5H4 www.boehringer-ingelheim.ca Date of Revision: June 6, 2019 Submission Control No: 225731 Giotrif ® is a registered trademark and used under license from Boehringer Ingelheim International GmbH BICL 0281-09 _Pr_ _GIOTRIF® Product Monograph _ _ Page 2 of 44 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................11 DRUG INTERACTIONS ..................................................................................................19 DOSAGE AND ADMINISTRATION ..............................................................................20 OVERDOSAGE ................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY ............................................................22 STORAGE AND STABILITY ..........................................................................................23 SPECIAL HANDLING INSTRUCTIONS .......................................................................23 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................24 PART II : SCIENTIFIC INFORMATION ............................................................ पूरा दस्तावेज़ पढ़ें